In 2026, several critical phase 3 readouts could reshape the landscape of their respective indications. We list 11 Phase 2 and Phase 3 trials, with trial registry primary completion dates from December 2026 to July 2028. Understanding these clinical trial results can significantly influence investment decisions.
Cognition CT1812 Alzheimer's: Phase 2 Readout 2027
The full Phase 2 and Phase 3 readouts to watch
| Registry primary completion | Ticker | Drug | Indication | Phase | PoA |
|---|---|---|---|---|---|
| 2027-04 | CGTX | CT1812, Placebo (-7% run-up) | Early Alzheimer's Disease | PHASE2 | n/a |
| 2026 (company release) | MNOV | MN-166, placebo (+10.2% run-up) | Amyotrophic Lateral Sclerosis | PHASE2 | n/a |
| Reported September 2026 | MNOV | MN-001, MN-001 placebo (+10.2% run-up) | Diabetes Mellitus, Type 2 | PHASE2 | n/a |
| Q1 2027 (company release) | MLTX | Sonelokimab | Hidradenitis Suppurativa | PHASE3 | n/a 🔒 |
| Reported August 2026 | MLTX | Sonelokimab, Placebo | Arthritis, Psoriatic | PHASE3 | n/a 🔒 |
| Reported November 2026 | CORT | Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B) | Nonalcoholic Steatohepatitis (NASH) | PHASE2 | n/a 🔒 |
| 2026-12 | CORT | relacorilant | Cushing Syndrome | PHASE2 | n/a 🔒 |
| 2028-01-26 | REGN | BNT116, Cemiplimab | Advanced Non-Small Cell Lung Cancer | PHASE2 | n/a 🔒 |
| 2026-12-12 (company release, ASH data) | GILD | anitocabtagene-autoleucel | Multiple Myeloma | PHASE2 | n/a 🔒 |
| 2028-07 | GILD | Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib | Multiple Myeloma | PHASE3 | n/a 🔒 |
| First half of December 2026 (company) | BIIB | Litifilimab, Placebo | Lupus Erythematosus, Systemic | PHASE3 | n/a 🔒 |
Dates are trial registry primary completion dates, not company guidance.
CGTX's CT1812: A Phase 2 Readout for Early Alzheimer's Disease
The trial registry lists primary completion of the Phase 2 CT1812 study in Early Alzheimer's Disease in April 2027. This follows a -7% run-up, signaling possible market skepticism or profit-taking. CT1812 targets the toxic effects of amyloid-beta, a key factor in Alzheimer's pathology. Positive results could mean a significant upside for CGTX, but disappointing outcomes might worsen the current downward trend. We'll be watching insider activity and market sentiment closely as this trial nears completion.
MNOV's MN-166: Insights on Amyotrophic Lateral Sclerosis
MediciNova expects topline results from the COMBAT-ALS trial of MN-166 by the end of 2026, aimed at treating Amyotrophic Lateral Sclerosis (ALS), a condition lacking many treatment options. The stock has seen a 10.2% run-up, hinting at investor optimism. Known for its neuroprotective properties, MN-166 could offer a new treatment avenue. However, a failure could sharply drop MNOV's stock price. We'll examine the trial's efficacy and safety, crucial for this vulnerable patient group.
MNOV's MN-001: A Phase 2 Readout for Type 2 Diabetes
MNOV has since reported topline results from its Phase 2 MN-001 trial in Type 2 Diabetes (September 2026). The stock had a 10.2% run-up before the results. MN-001 aims to improve insulin sensitivity, crucial for diabetes management. The competitive diabetes therapy market makes these results pivotal. The results will shape MNOV's position in the diabetes market.
Gated Items: A Broader Look at Upcoming Phase 3 Readouts
Beyond the Phase 2 trials above, eight gated items round out the table. MLTX has since reported Week 52 results for Sonelokimab in Hidradenitis Suppurativa from the Phase 3 VELA program (June 2026). Effective treatments for this condition remain few. CORT has since reported results from the Phase 2b MONARCH trial of Miricorilant in Nonalcoholic Steatohepatitis (NASH), a growing concern with the rise of metabolic syndrome (November 2026). These trials could significantly influence company valuations. We'll assess the market impact of these results.
The Importance of Timing in Phase 3 Readouts
Timing is crucial for phase 3 readouts. BIIB expects topline data from the Phase 3 TOPAZ-1 and TOPAZ-2 studies of Litifilimab in Systemic Lupus Erythematosus in the first half of December 2026. Lupus treatments have historically struggled to show efficacy, making this data critical. The timing of these readouts often impacts stock performance, as investors react to both results and the market context. We'll watch market sentiment and any insider trading activity that might signal investor confidence or doubt.
Risk Factors Associated with Phase 3 Readouts
Investing around phase 3 readouts carries significant risk. GILD plans to present updated iMMagine-1 data for anitocabtagene autoleucel in Multiple Myeloma at ASH on December 12, 2026, and the trial registry lists primary completion of the Phase 3 study in July 2028. Success might boost stock prices, but negative results could severely impact investor confidence. The complexity of oncology trials raises the stakes. We will evaluate efficacy and safety data to gauge these candidates' long-term viability. Understanding these risks is essential for informed investment decisions.
The bottom line
Staying informed about these pivotal phase 3 readouts will be key to making sound investment decisions.